Global Targeted Radiotherapy Drug Supply, Demand and Key Producers, 2023-2029

Global Targeted Radiotherapy Drug Supply, Demand and Key Producers, 2023-2029

The global Targeted Radiotherapy Drug market size is expected to reach $ 8868.3 million by 2029, rising at a market growth of 5.6% CAGR during the forecast period (2023-2029).

Targeted radiotherapy is a medical treatment designed to direct radioactive isotopes to specific types of tumor cells or tumor markers, allowing for precise tumor treatment. These drugs offer a promising treatment for some malignant tumors, especially those that are advanced or difficult to surgically remove. As technology develops, treatment effects, as well as patient survival and quality of life after treatment, can be better monitored and evaluated. The development trend of targeted radiotherapy drugs emphasizes precise treatment, personalized treatment and comprehensive treatment methods. This will hopefully provide more effective cancer treatments in the future and improve patient survival and quality of life.

This report studies the global Targeted Radiotherapy Drug demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Targeted Radiotherapy Drug, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Targeted Radiotherapy Drug that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Targeted Radiotherapy Drug total market, 2018-2029, (USD Million)

Global Targeted Radiotherapy Drug total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Targeted Radiotherapy Drug total market, key domestic companies and share, (USD Million)

Global Targeted Radiotherapy Drug revenue by player and market share 2018-2023, (USD Million)

Global Targeted Radiotherapy Drug total market by Type, CAGR, 2018-2029, (USD Million)

Global Targeted Radiotherapy Drug total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Targeted Radiotherapy Drug market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Bayer, Endocyte, Progenics Pharmaceuticals, Jubilant Radiopharma, Curium, Fermi Energia and Nucleus RadioPharma, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Targeted Radiotherapy Drug market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Targeted Radiotherapy Drug Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Targeted Radiotherapy Drug Market, Segmentation by Type
Radioactive Iodine Therapeutic Drugs
Radioactive Antibody Therapeutic Drugs
Others

Global Targeted Radiotherapy Drug Market, Segmentation by Application
General Hospital
Specialty Hospital

Companies Profiled:
Novartis
Bayer
Endocyte
Progenics Pharmaceuticals
Jubilant Radiopharma
Curium
Fermi Energia
Nucleus RadioPharma

Key Questions Answered

1. How big is the global Targeted Radiotherapy Drug market?

2. What is the demand of the global Targeted Radiotherapy Drug market?

3. What is the year over year growth of the global Targeted Radiotherapy Drug market?

4. What is the total value of the global Targeted Radiotherapy Drug market?

5. Who are the major players in the global Targeted Radiotherapy Drug market?